Cubist Pharmaceuticals, Inc. Reports First Quarter 2007 Results: Total Revenues $59.5 Million; Net Product Revenues $59.4 Million

LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today reported results for the first quarter ended March 31, 2007. Net sales of CUBICIN® (daptomycin for injection) increased 57% from the prior year, from $37.9 million in the first quarter of 2006 to $59.4 million in the first quarter of 2007. U.S. net product revenue was $57.5 million. Total revenues for the first quarter of 2007 increased 48% over the first quarter of 2006 from $40.1 million in the first quarter of 2006 to $59.5 million in the first quarter of 2007.